Shun Lu

机构：Shanghai Jiao Tong University, Shanghai Chest Hospital

发表论文 19 篇 · 总被引 656 次 · h-index 11

代表论文

• Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer (2025 · New England Journal of Medicine · 被引 208)
• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 113)
• Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer (2025 · New England Journal of Medicine · 被引 53)
• Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial (2024 · The Lancet Respiratory Medicine · 被引 42)
• Consensus on the lung cancer management after third-generation EGFR-TKI resistance (2024 · The Lancet Regional Health - Western Pacific · 被引 27)
• First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. (2025 · Journal of Clinical Oncology · 被引 22)